HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
Open Access
- 16 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Gastroenterology
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12876-020-01531-5
Abstract
Amplification of HER2 gene (ERBB2) and overexpression of HER2 protein on cancer cells are found in 10–26% of gastric cancer (GC) and esophagogastric junction cancer (EGJC). Gene copy number variation (CNV) could be detected in these patients in liquid biopsy and in cancer cells. We analysed HER2 gene CNV used qPCR method in 87 sera collected from GC and EGJC patients before surgical treatment and in 40 sera obtained from healthy donors. HER2 gene CNV was also assessed in formalin-fixed paraffin-embedded (FFPE) tumor tissue. Furthermore, we assessed the number of HER2 gene copies and HER2 expression in cancer cells using the fluorescent in situ hybridization method (FISH) and immunohistochemistry (IHC). We found that the HER2 gene copy number in liquid biopsy was higher in GC and EGJC patients compared to healthy people (p = 0.01). Moreover, EGJC patients had higher number of HER2 gene copies than healthy donors (p = 0.0016). HER2 CNV examination could distinguish healthy individuals and patients with gastric or esophagogastric junction cancers with sensitivity and specificity of 58% and 98% (AUC = 0.707, 95% CI 0.593–0.821, p = 0.004). We found that patients with a high copy number of the HER2 gene in the tumor tissue assessed by qPCR (but not by FISH) have significantly more often a high number of HER2 gene copies in liquid biopsy (p = 0.04). We suggested that HER2 testing in liquid biopsy could be used as an auxiliary method to analysis of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.Keywords
Other Versions
This publication has 30 references indexed in Scilit:
- Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patientsJapanese Journal of Clinical Oncology, 2014
- HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot studyGastric Cancer, 2014
- Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistryExperimental and Therapeutic Medicine, 2014
- Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: A study of 55 casesMolecular Medicine Reports, 2014
- Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapyWorld Journal of Gastroenterology, 2014
- Gastric cancer and trastuzumab: first biologic therapy in gastric cancerTherapeutic Advances in Medical Oncology, 2013
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysisAnnals of Oncology, 2012
- HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US PopulationApplied Immunohistochemistry & Molecular Morphology, 2012
- Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parametersThe Breast, 2010
- Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survivalAnnals of Oncology, 2008